News headlines about Infinity Pharmaceuticals (NASDAQ:INFI) have trended somewhat positive this week, according to Alpha One Sentiment. The research firm, a subsidiary of Accern, identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a news impact score of 0.08 on Alpha One’s scale. Alpha One also assigned media headlines about the biotechnology company an impact score of 90 out of 100, meaning that recent media coverage is very likely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Alpha One Sentiment’s scoring:
- AbbVie (ABBV) Presents Positive Data on HCV Combination Drug (zacks.com)
- Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline to Witness Increased R&D Investment in the Coming Years : P&S Market Research (abnewswire.com)
- Today’s Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals – Yahoo Finance (finance.yahoo.com)
- Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% – Yahoo Finance (finance.yahoo.com)
- Where Technical Charts Stands for Huntington Bancshares Incorporated (HBAN) (naijaoversabi.com)
Infinity Pharmaceuticals (NASDAQ:INFI) traded down 2.54% on Friday, hitting $1.92. The stock had a trading volume of 683,425 shares. The company’s 50 day moving average price is $2.83 and its 200-day moving average price is $1.92. Infinity Pharmaceuticals has a 12-month low of $0.84 and a 12-month high of $6.63. The company’s market cap is $96.82 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, March 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. Infinity Pharmaceuticals had a negative return on equity of 125.20% and a net margin of 13.23%. The company’s quarterly revenue was down 100.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.80) earnings per share. Equities research analysts anticipate that Infinity Pharmaceuticals will post ($1.12) EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Very Likely to Affect Infinity Pharmaceuticals (INFI) Share Price” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.themarketsdaily.com/2017/04/21/somewhat-positive-news-coverage-very-likely-to-affect-infinity-pharmaceuticals-infi-share-price.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.